Glaucoma Surgery Devices Market

SKU: DMMD246 | Last Updated On: Jan 19 2023 | Available Formats

> Glaucoma Surgery Devices Market Expected to reach a high CAGR of 24.60% By 2023-2030:

Glaucoma Surgery Devices Market is segmented By Product Type (Punches, USC Marker, USC Planer, USC Shaver, Forceps, Others), By Surgery Type (Trabeculectomy, Tube Shunt Implantation, Cyclophotocoagulation, MIGS, Others), By End Users (Eye Hospitals, Diagnostic Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

[150 Pages Report] Glaucoma Surgery Devices Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 24.60% during the forecast period (2023-2030). Glaucoma is a set of ocular ailments that can induce vision loss and blindness by injuring the optic nerve. The aqueous humor, fluid inside the eye, usually rushes out of the eye via a mesh-like channel. If this channel gets clogged, excessive aqueous humor production may increase the intraocular pressure damaging the optic nerve. Glaucoma usually affects both eyes, whereas it may be more alarming in one than the other.

Glaucoma Surgery Devices Market - Strategic Insights

Metrics

Details

Market CAGR

24.60%

Segments Covered

By Product Type, By Surgery Type, By End Users and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Market Dynamics

Glaucoma surgery advancements, new product developments, increased encounters of cases, and growing awareness about glaucoma fuel the global market growth.

Glaucoma surgery advancements and the increasing burden of glaucoma worldwide are pushing the global market growth.

Glaucoma surgery advancements fuel global market growth, such as the development of minimally invasive glaucoma surgery (MIGS), subconjunctival MIGS, and cyclophotocoagulation. MIGS is a bunch of procedures otherwise comprehended as an angle-based procedure that comprises Trabecular bypass stents, such as iStent (Glaukos) and Hydrus (Ivantis), Trabecular removal, such as Trabectome (MicroSurgical Technology), Kahook Dual Blade (New World Medical), and Goniotome (MicroSurgical Technology), Trabecular unroofing, such as gonioscopic-assisted transluminal trabeculotomy, or GATT, and OMNI (Sight Sciences), Schlemm’s canal dilation via ab interno canaloplasty (Ellex), and Suprachoroidal stents.

Furthermore, the growing encounters of glaucoma globally are driving the global market growth. According to the World Glaucoma Association, established on prevalence studies, it is assessed that over 79.6 million individuals had glaucoma in 2020, and it is predicted to rise to around 111.8 million individuals by 2040. A minimum of 50% of those with glaucoma are unaware they are affected. In a few developing nations, 90% of glaucoma is undetected.

The risks and high cost are major concerns for the glaucoma surgery devices market growth.

However, the high cost of glaucoma surgery will hamper the global market growth during the forecast period. For instance, a laser surgery considered a low-cost surgery costs $1,000 to $2,000, whereas an Incisional surgery will cost around $11,000.

COVID-19 Impact Analysis

During the pandemic, glaucoma management was difficult to perform, which led to shifting the focus on teleglaucoma, such as the advancements in home monitoring of intraocular pressure (IOP) and visual fields. For instance, Icare USA developed the Rebound tonometer authorized for IOP measurements. Also, the Eyemate telemetric IOP sensor is newly endorsed for usage in Europe and works as a permanent implantable monitoring device for patients with open-angle glaucoma.

Furthermore, the frequency of trabeculectomies declined in the COVID-19 outburst partly because of the number of postoperative visits and procedures required; as a result, the conventional and micropulse diode laser, glaucoma drainage devices, deep sclerectomy and Preserflo seem to resort as they require less intensive postoperative care. The need to minimize patient contact during surgery and facilitate postoperative supervision to downsize the risk of COVID-19 transmission has immensely influenced the choice of surgery type proposed after the outburst with an inclination to lower postoperative follow-up, interventions, and shorter surgical time, which has significantly affected the glaucoma surgical device market.

Segment Analysis

The Minimally Invasive Glaucoma Surgeries (MIGS) are expected to grow at the fastest CAGR during the forecast period (2022-2029)

Minimally Invasive Glaucoma Surgeries (MIGS) are anticipated to dominate the global market in the forecast period (2022-2029). Since the other surgeries have a long list of potential complications, there is an increased need for minimally invasive glaucoma surgeries because they offer equivalent IOP-lowering capabilities compared to traditional incisional surgeries but with an improved safety profile. Furthermore, the approval for minimally invasive glaucoma surgery devices ensures the dominance of MIGS over the global market; for example, in November 17, 2021, iSTAR Medical received European market approval for glaucoma implant MINIject. Also, in August 03, 2022, the U.S. Food and Drug Administration (FDA) granted approval to Glaukos Corporation for its iStent infinite, a trabecular micro-bypass system meant for usage in a standalone procedure to lessen elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma unchecked by previous medical and surgical treatment.

Geographical Analysis

The North American region hosts the largest share of the glaucoma surgery devices market.

North America dominates the global glaucoma surgery devices market. It is predicted to dominate throughout the forecast period (2022-2029) owing to the presence of a majority of market players holding a larger share of the global market through different market tactics such as product launches, approvals, acquisitions, expansions, Etc in this region. Such as, in June 08, 2022, Corza Medical, a leading global manufacturer of innovative surgical technologies in the United States, acquired Barron Precision Instruments, expanding its portfolio of ophthalmic surgery products; in March 7, 2022, Alcon, a U.S.-based ophthalmic devices company launched its Clareon IOL Portfolio in the U.S. strengthening its hold over the ophthalmic market also, in January 10, 2022, Alcon acquired Ivantis, Inc., adding Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surgery. Also, the high incidences of glaucoma among the American population are fueling the dominance of this region over the global market; for instance, CDC states that over 3 million Americans have glaucoma making it one of the foremost reasons for irreversible blindness in the United States and costing the U.S. economy $2.86 billion every year in direct costs and productivity losses. Also, it is predicted that glaucoma will affect over 6.3 million Americans by 2050.

Competitive Landscape

The expanding innovation on glaucoma surgery devices obligates the market players to be competitive to keep a place in the market, making the glaucoma surgery devices market Corza Medical, Alcon, Inami & Co., Ltd., Katalyst Surgical, Lumenis, Millennium Surgical, Moria Surgical, Zabbys, Johnson & Johnson and Allergan are key players. These key players hold most of the market share through innovations, product launches, collaborations, acquisitions, and alliances. For instance, in September 16, 2021, Johnson & Johnson Vision, part of the Johnson & Johnson Medical Devices Companies, collaborated with Black EyeCare Perspective, a not-for-profit organization.

Johnson & Johnson

Overview:

J&J was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, in Brunswick, New Jersey, United States. J&J is on a mission to keep people well at every age and every stage of life. It is the world’s largest and most broadly-based healthcare company committed to using its reach and size for innovation in healthcare.

Product Portfolio:

J&J glaucoma surgery devices portfolio includes iFS Advanced Femtosecond Laser: iFS Laser is an extensive platform created on IntraLase Technology’s heritage of surgical accuracy. Providing fully individualized procedures from LASIK flaps to inlay pocket creation, the iFS Laser is the perfect option for every ophthalmic subspecialty, BAERVELDT Glaucoma Implants: Provide pressure control in a minimally invasive way, has a fenestration system designed for controlling bleb height and volume, whereas the patented more extensive surface area improves IOP control. Used When traditional glaucoma therapy can’t help the rising IOP.

The global glaucoma surgery devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Trending Topics

Cataract Surgery Devices Market

Bariatric Surgery Devices Market

Cardiac Surgery Devices Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest